Daniel Lochner
Director of Finance/CFO presso OYSR POIN
Profilo
Daniel Lochner is currently the Chief Financial & Business Officer at Oyster Point Pharma, Inc. He previously worked as a Portfolio Manager at Goldman Sachs Asset Management LP from 2005 to 2019.
Mr. Lochner holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Richmond.
Posizioni attive di Daniel Lochner
| Società | Posizione | Inizio |
|---|---|---|
| OYSR POIN | Director of Finance/CFO | 01/07/2019 |
Precedenti posizioni note di Daniel Lochner
| Società | Posizione | Fine |
|---|---|---|
Goldman Sachs Asset Management LP
 Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Portfolio Manager-Equities | 01/07/2019 |
Formazione di Daniel Lochner
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| University of Richmond | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Goldman Sachs Asset Management LP
Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Finance |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
- Borsa valori
- Insiders
- Daniel Lochner
